Osage University Partners has thrown its weight behind a series A2 round for Artizan, which is advancing work undertaken at Yale University.
Artizan Biosciences, a US-based developer of treatments for inflammatory diseases that was spun out of Yale University, has collected $11m in a series A2 round backed by spinout-focused investment firm Osage University Partners (OUP).
Biopharmaceutical firm Biohaven Therapeutics and Hatteras Venture Partners co-led the round, which also attracted Connecticut Innovations and Elm Street Ventures.
Artizan is working on therapies for inflammatory diseases linked to the intestinal microbiota. It will use the financing to advance the preclinical development of…
Thierry Heles
Thierry Heles is the editor of Global University Venturing, host of the Beyond the Breakthrough interview podcast and responsible for the monthly GUV Gazette (sign up here for free).
